1 Holch JW, Westphalen CB, Hiddemann W, et al. Precision Oncology and «Molecular Tumor Boards» – Concepts, Chances and Challenges. Dtsch Med Wochenschr. 2017;142:1676–84.
2 Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR muta-tion-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46.
3 Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724–34.
4 Subbiah V, Kurzrock R. Debunking the Delusion That Precision Oncology Is an Illusion. Oncologist. 2017;22:881–2.
5 Prasad V. Perspective: The precision-oncology illusion. Nature. 2016;537:63.
6 Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10 000 patients. Nat Med. 2017;23:703–13.
7 Le Tourneau C, Delord JP, Goncalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16:1324–34.
8 Tsimberidou AM, Kurzrock R. Precision medicine: lessons learned from the SHIVA trial. Lancet Oncol. 2015;16:579–80.
9 Schwaederle M, Zhao M, Lee JJ et al. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol. 2015;33:3817–25.
11 Mateo J, Chakravarty D, Dienstmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol 2018.
12 Hyman DM, Smyth LM, Donoghue MTA, et al. AKT Inhibition in Solid Tumors With AKT1 Mutations. J Clin Oncol. 2017;35:2251–9.
13 https://www.sphn.ch/en/projects/driver-projects.html.